Skip to main
FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics Inc. is recognized as a leading developer of induced pluripotent stem cell (iPSC)-derived cancer therapeutics, particularly focusing on NK and T-cell immunotherapies. The company has recently reported promising initial clinical data, demonstrating the effectiveness of its off-the-shelf CD19 CAR-T (FT819) in patients with systemic lupus erythematosus, significantly improving key disease markers without severe adverse effects. Additionally, the allogeneic nature of FT819 enhances its potential for re-dosing strategies, which positions Fate for scalable, cost-effective manufacturing and addresses critical challenges within the cellular therapeutics field.

Bears say

Fate Therapeutics Inc. faces several risks that contribute to a negative outlook on its stock, including the potential inability to demonstrate a significant clinical efficacy advantage of FT819 compared to existing CAR-T therapies. Additionally, there are concerns regarding safety and immunogenicity, which could raise alarms with regulatory agencies and impact future partnerships. The company also faces a medium-term dilution risk, further complicating its financial outlook amid mixed clinical results observed in its efficacy evaluable patients.

Fate Therapeutics (FATE) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 5 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.